A5086868653- Protein purification and stability
- Retinal Diseases and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Retinal Development and Disorders
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Retinal and Macular Surgery
- Lung Cancer Treatments and Mutations
- Pharmaceutical studies and practices
- Radiopharmaceutical Chemistry and Applications
- Glycosylation and Glycoproteins Research
- Retinal and Optic Conditions
- Retinopathy of Prematurity Studies
- HER2/EGFR in Cancer Research
- Safe Handling of Antineoplastic Drugs
- Transgenic Plants and Applications
- Glaucoma and retinal disorders
Roche (United States)
2023-2025
Sangamo BioSciences (United States)
2020
Genentech
2012
Development of intravitreal drugs presents several challenges due to the delicate ocular environment and volume constraints what can be safely administered in eye. Formulation development intravitreally may necessitate use nonphysiological pH order accommodate manufacturing processes or achieve favorable drug properties. Clinical nonclinical data show that formulated 5.5 7.4 range are well tolerated. The aim this study was provide toxicity for formulations 4.0 following administration New...
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system that has the potential to reduce treatment burden in patients retinovascular diseases. Platform (PD-P) implant a permanent, indwelling device can be refilled situ through self-sealing septum and designed continuously deliver by passive diffusion porous titanium release control element. We present results for studies carried out characterize stability of use PD-P. Simulated administration, vitro...